Park SH - Search Results

1

Dynamic change of T315I BCR-ABL kinase domain mutation in Korean chronic myeloid leukaemia patients during treatment with Abl tyrosine kinase inhibitors.

Kim WS, Kim D, Kim DW, Kweon IY, Kim SH, Goh HG, Park SH, Lee J. Kim WS, et al. Among authors: park sh. Hematol Oncol. 2010 Jun;28(2):82-8. doi: 10.1002/hon.918. Hematol Oncol. 2010. PMID: 19768693

2

Structural modeling of V299L and E459K Bcr-Abl mutation, and sequential therapy of tyrosine kinase inhibitors for the compound mutations.

Kim D, Kim DW, Cho BS, Goh HG, Kim SH, Kim WS, Lee J, Kweon IY, Park SH, Yoon JH, Kim ND, Chun H. Kim D, et al. Among authors: park sh. Leuk Res. 2009 Sep;33(9):1260-5. doi: 10.1016/j.leukres.2008.12.017. Epub 2009 Feb 6. Leuk Res. 2009. PMID: 19201023

3

Analysis of Bcr-Abl kinase domain mutations in Korean chronic myeloid leukaemia patients: poor clinical outcome of P-loop and T315I mutation is disease phase dependent.

Kim SH, Kim D, Kim DW, Goh HG, Jang SE, Lee J, Kim WS, Kweon IY, Park SH. Kim SH, et al. Among authors: park sh. Hematol Oncol. 2009 Dec;27(4):190-7. doi: 10.1002/hon.894. Hematol Oncol. 2009. PMID: 19274615

4

Previous best responses can be re-achieved by resumption after imatinib discontinuation in patients with chronic myeloid leukemia: implication for intermittent imatinib therapy.

Goh HG, Kim YJ, Kim DW, Kim HJ, Kim SH, Jang SE, Lee J, Kim D, Kim WS, Park SH, Kweon IY. Goh HG, et al. Among authors: park sh. Leuk Lymphoma. 2009 Jun;50(6):944-51. doi: 10.1080/10428190902926973. Leuk Lymphoma. 2009. PMID: 19479613

5

Effects of imatinib mesylate on the pharmacokinetics of paracetamol (acetaminophen) in Korean patients with chronic myelogenous leukaemia.

Kim DW, Tan EY, Jin Y, Park S, Hayes M, Demirhan E, Schran H, Wang Y. Kim DW, et al. Br J Clin Pharmacol. 2011 Feb;71(2):199-206. doi: 10.1111/j.1365-2125.2010.03810.x. Br J Clin Pharmacol. 2011. PMID: 21219400 Free PMC article.

6

Comprehensive therapeutic outcomes of frontline imatinib mesylate in newly diagnosed chronic phase chronic myeloid leukemia patients in Korea: feasibility assessment of current ELN recommendation.

Kim D, Goh HG, Kim SH, Choi SY, Park SH, Jang EJ, Kim DW. Kim D, et al. Among authors: park sh. Int J Hematol. 2012 Jul;96(1):47-57. doi: 10.1007/s12185-012-1093-y. Epub 2012 May 19. Int J Hematol. 2012. PMID: 22610512

7

Efficacy and safety of radotinib in chronic phase chronic myeloid leukemia patients with resistance or intolerance to BCR-ABL1 tyrosine kinase inhibitors.

Kim SH, Menon H, Jootar S, Saikia T, Kwak JY, Sohn SK, Park JS, Jeong SH, Kim HJ, Kim YK, Oh SJ, Kim H, Zang DY, Chung JS, Shin HJ, Do YR, Kim JA, Kim DY, Choi CW, Park S, Park HL, Lee GY, Cho DJ, Shin JS, Kim DW. Kim SH, et al. Among authors: park s, park js, park hl. Haematologica. 2014 Jul;99(7):1191-6. doi: 10.3324/haematol.2013.096776. Epub 2014 Apr 4. Haematologica. 2014. PMID: 24705186 Free PMC article. Clinical Trial.

8

Integrative genomic analysis reveals cancer-associated mutations at diagnosis of CML in patients with high-risk disease.

Branford S, Wang P, Yeung DT, Thomson D, Purins A, Wadham C, Shahrin NH, Marum JE, Nataren N, Parker WT, Geoghegan J, Feng J, Shanmuganathan N, Mueller MC, Dietz C, Stangl D, Donaldson Z, Altamura H, Georgievski J, Braley J, Brown A, Hahn C, Walker I, Kim SH, Choi SY, Park SH, Kim DW, White DL, Yong ASM, Ross DM, Scott HS, Schreiber AW, Hughes TP. Branford S, et al. Among authors: park sh. Blood. 2018 Aug 30;132(9):948-961. doi: 10.1182/blood-2018-02-832253. Epub 2018 Jul 2. Blood. 2018. PMID: 29967129 Free article. Clinical Trial.

9

Early BCR-ABL1 kinetics are predictive of subsequent achievement of treatment-free remission in chronic myeloid leukemia.

Shanmuganathan N, Pagani IS, Ross DM, Park S, Yong ASM, Braley JA, Altamura HK, Hiwase DK, Yeung DT, Kim DW, Branford S, Hughes TP. Shanmuganathan N, et al. Blood. 2021 Mar 4;137(9):1196-1207. doi: 10.1182/blood.2020005514. Blood. 2021. PMID: 32871588 Free article.

10

AMD1 is required for the maintenance of leukemic stem cells and promotes chronic myeloid leukemic growth.

Sari IN, Yang YG, Wijaya YT, Jun N, Lee S, Kim KS, Bajaj J, Oehler VG, Kim SH, Choi SY, Park SH, Kim DW, Reya T, Han J, Kwon HY. Sari IN, et al. Among authors: park sh. Oncogene. 2021 Jan;40(3):603-617. doi: 10.1038/s41388-020-01547-x. Epub 2020 Nov 17. Oncogene. 2021. PMID: 33203990

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

11,230 results

Search Page

Filters